# PENK Methylation Test for Detecting Bladder Cancer

> **NCT05220189** · — · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 1549 (estimated)

## Conditions studied

- Bladder Cancer
- Hematuria; Benign

## Interventions

- **DIAGNOSTIC_TEST:** EarlyTect® Bladder Cancer test

## Key facts

- **NCT ID:** NCT05220189
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-03
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 1549 (ESTIMATED)
- **Last updated:** 2023-10-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220189, "PENK Methylation Test for Detecting Bladder Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05220189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*